spacer gif spacer gif spacer gif spacer gif spacer gif
 QUICK SEARCH:   [advanced]


spacer gif
     Home     Help     Feedback     Subscriptions     Archive     Search     Table of Contents    

First published online December 11, 2006


Journal of Cell Science 119, 2404e (2006)
© The Company of Biologists Limited
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in JCS
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

In this issue

NO limit to muscular dystrophy


Figure 1

Muscular dystrophies are untreatable, sometimes fatal, genetic diseases that are characterized by progressive wasting of skeletal muscle. Stem-cell-based therapies, such as the injection of mesoangioblasts (blood-vessel-associated myogenic stem cells), have usually stimulated only limited muscle repair in animal models of muscular dystrophy. But, on p. 5114, Giulio Cossu, Emilio Clementi and co-authors report that ex-vivo treatment of mesoangioblasts with nitric oxide (NO) donors increases their therapeutic efficacy in the {alpha}-sarcoglycan-null mouse model of Duchenne muscular dystrophy. NO treatment, they report, enhances the migration of mesoangioblasts to the dystrophic muscles of these mice and helps the mesoangioblasts resist the apoptogenic environment of these muscles and engraft. The authors replicate these beneficial effects of NO in vitro and show that all the effects are GMP-dependent. Finally, they report that NO switches on signalling pathways in the mesoangioblasts that are involved in myogenesis and muscle repair. Thus, the authors conclude, treatment with NO might be a simple way to improve the efficacy of stem-cell therapy for muscle-wasting disorders.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?

Related articles in JCS:

Ex vivo treatment with nitric oxide increases mesoangioblast therapeutic efficacy in muscular dystrophy
Clara Sciorati, Beatriz G. Galvez, Silvia Brunelli, Enrico Tagliafico, Stefano Ferrari, Giulio Cossu, and Emilio Clementi
JCS 2006 119: 5114-5123. [Abstract] [Full Text]  




This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in JCS
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?